The excellent innovative work of Squibb Laboratory scientists in the 1970’s led to the discovery of the ACE inhibitors and the ARBs. Despite their widespread use, for renoprotection, we have continued to experience a global ESRD pandemic. Angiotensin blockade has proved inadequate. In 2010, we asked the rhetorical question: Is renoprotection with RAAS blockade a failed paradigm?
Keywords: Angiotensin receptor blockers, ACE inhibitors, chronic kidney disease, diabetes mellitus, novel classification scheme, revisionist view, renoprotection, renoprotective agents.
About this chapter
Cite this chapter as:Macaulay A.C. Onuigbo ;
Angiotensin Blockers and Renoprotection in Diabetic Chronic Kidney Disease is a Failed Paradigm? – A Revisionist View of Renoprotection in Diabetic Chronic Kidney Disease and A Novel Classification Scheme for Renoprotective Agents, Frontiers in Clinical Drug Research-Diabetes and Obesity (2014) 1: 3. https://doi.org/10.2174/9781608058563114010003
Bentham Science Publisher